drugset
drugset / Trial / NCT00443261

Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT00443261 ↗

Phase 1 Terminated 1 enrolled University of Kansas Medical Center Celgene Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and toxicity of azacitidine (5-azacitidine, Vidaza®) and cisplatin combination in patients with squamous cell carcinoma of head and neck (SCCHN).

Timeline

Start
2007-02
Primary completion
2008-06
Completion
2008-06

Outcome

Outcome not reported

Stopped (Enrollment): “Accrual problems”

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified — Subcutaneous
Subject Cisplatin Other / unclassified 75 mg/m2 Intravenous

Indications

squamous cell carcinoma